<?xml version="1.0" encoding="UTF-8"?>
<p>The primary outcome is the time to 2019-nCoV RNA negativity in patients. The secondary outcomes are: the rate of negative 2019-nCoV RNA results at day 14; the mortality rate for COVID-19 patients at day 28 after antiviral therapy; the rate of patients re-classified as severe cases during the study period; the rate of adverse events during the study period, and the rate of therapeutic discontinuation due to adverse events during the study period.</p>
